Ebanga, developed by Ridgeback Biotherapeutics, was approved by the FDA on December 21, 2020 for the treatment for Zaire ebolavirus (Ebolavirus) infection in adults and children.Ebanga (ansuvimab-zykl), a human monoclonal antibody works by blocking binding of the virus to the cell receptor, preventing its entry into the cell.Zaire ebolavirus is one of four Ebolavirus species that can cause a potentially fatal human disease.Regeneron's Inmazeb, approved in October last year is the first and only other approved treatment for Zaire ebolavirus.There is one vaccine that is indicated for the prevention of Ebola virus disease - Merck's Ervebo, approved in December 2020.Patients who receive Ebanga should avoid the concurrent administration of a live Ebolavirus vaccine as Ebanga has the potential to inhibit replication of a live vaccine virus and possibly reduce the efficacy of this vaccine.